BioPharma Reporter

JULY 5, 2021

Sartorius is strengthening its product portfolio for cell and gene therapies with the acquisition of a majority stake in German reagent manufacturer CellGenix.

Reagent 90

Reagent Gene Therapy Gene Manufacturing 90

Drug Discovery World

JANUARY 19, 2023

This paid-for advertorial by Catalent appeared in DDW Volume 24 – Issue 1, Winter 2022/2023 One significant challenge in the manufacturing of cell and gene therapies is the production of high-quality plasmid DNA (pDNA). Figure 1: The integrated development pathway for cell and gene therapies.

DNA 52

DNA Manufacturing Gene Therapy Gene 52

Drug Discovery World

SEPTEMBER 25, 2023

CRISPR gene editing companies Integrated DNA Technologies (IDT) and Aldevron have inked a new global distribution agreement to expand CRISPR products for cell and gene therapy customers.

Genome 52

Genome Genomics Gene Editing Medicine 52

Advarra

NOVEMBER 29, 2022

The field of cell and gene therapies (CGT) is constantly evolving, and there has been significant progress in this area of research. Recent Problems in Cell and Gene Therapy Development. Current Regulatory Trends in Cell & Gene Therapy. Trend One: Expected Growth in Cell and Gene Therapy IND filings.

Gene Therapy 52

Gene Therapy Gene Production Clinical Trials 52

Roots Analysis

OCTOBER 16, 2023

DNA and Gene Cloning involves the isolation of a DNA sequence of any species ( often a gene ) and its insertion into a vector to enable growth without any alteration in the original DNA sequence. There are some motifs, such as hairpin loops which hinder the usability of a gene.

DNA 40

DNA Gene Protein In-Vitro 40

Drug Discovery World

MAY 16, 2023

What are the global innovations in cell and gene therapy? Skills gap Bruce Levine, International Society for Cell & Gene Therapy (ISCT) Immediate Past President and Chair, Strategic Advisory Council, says a critical challenge that has become apparent for the CGT sector is the need for workforce development and training resources.

Gene Therapy 52

Gene Therapy Gene Manufacturing Marketing 52

Drug Discovery World

MARCH 13, 2023

The cell and gene therapy (CGT) landscape has grown significantly in the past year. One example: Zynteglo, a newly approved gene therapy priced at a record-breaking $2.8M The lesson taught by this predicament: All parties in CGT development and manufacturing should hold themselves to the highest level of accountability.

Gene Therapy 52

Gene Therapy Gene Manufacturing Development 52

FDA Law Blog

JANUARY 4, 2023

Brevig, Senior Regulatory Device and Biologics Expert — On December 7, 2022, FDA’s Center for Biologics Evaluation and Research (CBER) and the Office of Tissues and Advanced Therapies (OTAT) held a town hall to answer questions related to cell therapy and tissue-engineered products chemistry, manufacturing, and contr­­ols (CMC).

Reagent 59

Reagent Manufacturing Production Gene Therapy 59

Drug Discovery World

AUGUST 11, 2023

GenScript Biotech and T-MAXIMUM Biotech have formed a strategic collaboration to develop T-MAXIMUM’s CAR-T cell therapy using GenScript’s CRISPR nucleic acid reagents. GenScript will provide various CRISPR reagents to support the development of the universal CAR-T products from discovery to commercialisation.

Reagent 52

Reagent Development Gene Editing Production 52

Drug Discovery World

JANUARY 30, 2024

He said: “Increasing the level of automation and standardisation is not only the way to reduce manufacturing costs, but also paves the way for follow-on approvals once a platform technology is part of an approval.  One option is that manufacturers will need to provide a product guarantee or refund the cost in a pay-for-performance model.

Gene Therapy 71

Gene Therapy Manufacturing Gene Clinical Trials 71

Drug Discovery World

MARCH 27, 2023

Learn more about the trends, insights, and perspectives from ACROBiosystems as a manufacturer of cell therapy reagents, including topics like: CAR-NK research Developing new CAR constructs Evaluation CAR expression detection Role of GMP Manufacturing in cell therapy Download now.

Reagent 52

Reagent Manufacturing Development Research 52

BioTech 365

SEPTEMBER 2, 2020

Ready-to-use kit enables rapid adeno-associated virus (AAV) titer determinations during the manufacture of AAV vectors UPPSALA, Sweden–(BUSINESS WIRE)–Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction … Continue (..)

Protein 52

Protein Gene Therapy Reagent Gene 52

Drug Discovery World

AUGUST 11, 2023

The news headlines this week reflect the level of interest in cell & gene therapies (CGT) in the sector, particularly CAR-T, but also the importance of research collaborations to bring these therapies to patients. News round-up for by DDW Digital Content Editor Diana Spencer.

Gene Therapy 52

Gene Therapy Drugs Clinical Trials Clinical Trials 52

Drug Discovery World

MARCH 27, 2023

Cell therapy research has never been more exciting with all of the research ongoing.

Reagent 52

Reagent Manufacturing Development Drugs 52

The Pharma Data

OCTOBER 14, 2020

Bio-Techne’s Woburn facility produces Cloudz Cell Activation Kits, a magnetic-free bead-based technology for the robust and reliable expansion of immune cells, including T cells and NK cells, representing a pivotal component of the cell and gene therapy workflow. ” About Bio-Techne Corporation (NASDAQ: TECH).

Manufacturing 40

Manufacturing Reagent Gene Therapy Protein 40

Roots Analysis

FEBRUARY 21, 2022

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Moreover, the manual protocols require extensive manipulation, costly reagents and long duration of skilled genomic library production. Nanoparticles Contract Manufacturing.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

Drug Discovery World

MAY 7, 2024

mAb production involves extensive, complicated manufacturing operations with many biological raw materials that require detailed procedures and advanced technologies to ensure the quality and stability of the final product. As a result, single-use technologies were explored as a more sustainable approach to mAb manufacturing.

Antibody 59

Antibody Production Manufacturing Engineer 59

pharmaphorum

FEBRUARY 3, 2021

Dr Jennifer Harbottle, senior scientist in the R&D Base Editing team of PerkinElmer’s Horizon Discovery business, looks at progress made in the realms of biotechnology and next-generation diagnostics, vaccines and therapeutics, including the application of CRISPR-Cas9 gene editing in developing and refining cell therapies.

Gene Editing 94

Gene Editing Gene DNA Engineer 94

The Pharma Data

MAY 17, 2021

Academic centers should establish risk management programs to successfully commercialize cell and gene therapy products and to be a viable partner with contract research organizations (CROs) and manufacturers in developing these therapies. . Uharek is a hematologist and cell and gene therapy specialist at Berlin’s Charité Hospital.

Development 52

Development Gene Therapy Manufacturing Gene 52

Roots Analysis

FEBRUARY 23, 2022

In the past two years, close to 3,220 patents related to NGS library preparation kits and reagents have been filed / granted, indicating the heightened pace of innovation. In addition to industry players, various academic institutes have filed multiple patents in this domain. Next Generation Sequencing (NGS) Library Preparation Kits.

Genetics 52

Genetics DNA RNA Reagent 52

Drug Discovery World

JANUARY 10, 2023

We are vertically-integrated from immunisation through manufacturing and validation. Our catalog of over 6,500+ primary antibodies, 1,200+ secondary antibodies, and 50+ ELISA kits includes reagents for multiplex IF, flow cytometry, and more in fields including immunology, oncology, and neuroscience. Pillar 6: Genetic Strategies.

Antibody 52

Antibody Protein Reagent Scientist 52

Drug Discovery World

FEBRUARY 8, 2023

Svea Cheeseman , Refeyn, explains why better efficiency is needed to advance the production of viral vectors for use in gene therapies. Adeno-associated viruses (AAVs) are a promising, widely used vector for delivering gene therapies. Data were provided by the Cell and Gene Therapy Catapult (London, UK).

Gene Therapy 52

Gene Therapy Gene Antibody Production 52

Drug Discovery World

NOVEMBER 30, 2023

coli expression systems and is using high-throughput expression pipelines to screen constructs for optimal expression to generate protein and cellular reagents. To demonstrate the utility of the company’s SYNTAX system in gene assembly, the 1.7 kb Influenza A hemagglutinin gene was used as a model system.

Antibody 59

Antibody Protein Engineer In-Vivo 59

Drug Discovery World

APRIL 3, 2023

As the industry moves to reduce the use of animals in research and testing, aptamers also support here, as they are discovered, developed, and manufactured entirely in vitro , removing the need for animals in antibody discovery processes. For gene therapies, the current challenge faced by developers is targeted delivery.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

Drug Discovery World

JUNE 14, 2023

BCA members also operate the BCA Advanced Therapies Network which is a diverse, fully integrated portfolio of blood, cell, gene and tissue materials that support the development and delivery of advanced therapies. One example we are following with anticipation are the two FDA approvals for the first gene therapies for sickle cell disease.

Manufacturing 52

Manufacturing Production Gene Therapy Development 52

The Pharma Data

DECEMBER 2, 2020

ERS Genomics – Ireland’s ERS Genomics Limited, and Germany’s Vivlion GmbH, announced a non-exclusive license agreement granting Vivlion access to ERS Genomics’ CRISPR/Cas9 patent portfolio, to enhance Vivlion’s gene editing reagents and screening services. Horizon Discovery Group – U.K.-based for its cGMP-compliant CHOSOURCE platform.

Drugs 52

Drugs Gene Editing Genome Genomics 52

Drug Discovery World

FEBRUARY 27, 2023

By focusing on workflow simplification and expanded assay capabilities in a state-of-the-art microplate reader, complemented by our optimised reagent technologies, our team has created an all-around high-performing system built for today and the future.”

Drugs 52

Drugs Life Science Protein Scientist 52